NCT02314442 - A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

November 30, 2015

Conditions

Hypercholesterolemia

Interventions

DRUG

ALN-PCSSC

Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

calculated volume to match active comparator

Trial Locations (2)

Covance Clinical Research Unit, Leeds

Richmond Pharmacology, London